BioNotebook: Hyperion/Andromeda lead deal makers; Theravance tops public company fundraising
This article was originally published in Scrip
Executive Summary
Hyperion buying Andromeda; Zogenix sells Sumavel to Endo; Hydra/Boehringer collaborate; Medivation, OncoFusion partner; Theravance, Alimera raise debt; Sarepta, Agios sell stock; and Radius, Alder, Aldeyra set IPO terms.
You may also be interested in...
Amunix Raises $117m To Take Novel T-Cell Engager Into The Clinic
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.